Kazia Therapeuticsの評価平均
Kazia Therapeuticsの評価平均は何ですか。
Kazia Therapeutics Limitedの評価平均は2.00です。
評価平均の定義は何ですか。
Recommendation meanは、株式のアナリストの格付けの平均値で、1.0(強い買い)から5.0(強い売り)の範囲です。
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
ASXのセクタHealth Careにおける評価平均の企業と比べるKazia Therapeutics
Kazia Therapeuticsは何をしますか。
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Kazia Therapeuticsと類似の評価平均
- Cabot Oil & Gasの評価平均は1.96です。
- Truistの評価平均は1.96です。
- Delta Air Linesの評価平均は1.96です。
- Discover Servicesの評価平均は1.96です。
- United Micro Electronicsの評価平均は1.96です。
- Tapestry Incの評価平均は1.97です。
- Kazia Therapeuticsの評価平均は2.00です。
- Trip.com Ltdの評価平均は2.03です。
- Sherwin-Williams Coの評価平均は2.03です。
- Canadian Pacific Kansas Cityの評価平均は2.03です。
- Arista Networks Incの評価平均は2.03です。
- Anheuser-Busch InBev SA/NVの評価平均は2.03です。
- Celanese Corpの評価平均は2.04です。